Your browser is no longer supported. Please, upgrade your browser.
Settings
RETA Reata Pharmaceuticals, Inc. daily Stock Chart
RETA [NASD]
Reata Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.99 Insider Own0.40% Shs Outstand29.70M Perf Week-4.43%
Market Cap2.60B Forward P/E- EPS next Y-3.88 Insider Trans143.52% Shs Float21.30M Perf Month11.73%
Income-113.80M PEG- EPS next Q-1.11 Inst Own69.30% Short Float11.25% Perf Quarter-2.30%
Sales29.00M P/S89.67 EPS this Y-46.00% Inst Trans2.41% Short Ratio10.43 Perf Half Y42.84%
Book/sh-0.15 P/B- EPS next Y17.30% ROA-36.90% Target Price132.14 Perf Year163.50%
Cash/sh10.54 P/C8.31 EPS next 5Y- ROE380.00% 52W Range32.89 - 104.53 Perf YTD56.08%
Dividend- P/FCF- EPS past 5Y-10.60% ROI-82.50% 52W High-16.23% Beta-
Dividend %- Quick Ratio5.20 Sales past 5Y0.90% Gross Margin- 52W Low166.22% ATR4.47
Employees123 Current Ratio5.20 Sales Q/Q-75.90% Oper. Margin- RSI (14)52.02 Volatility4.22% 5.63%
OptionableYes Debt/Eq- EPS Q/Q-737.70% Profit Margin- Rel Volume0.52 Prev Close86.51
ShortableYes LT Debt/Eq- EarningsMay 09 BMO Payout- Avg Volume229.62K Price87.56
Recom- SMA201.62% SMA501.15% SMA20015.03% Volume119,085 Change1.21%
Sep-25-18Reiterated Leerink Partners Outperform $116 → $139
Sep-13-17Initiated Leerink Partners Outperform $43
Jul-25-17Reiterated Citigroup Buy $39 → $87
Apr-13-17Initiated Ladenburg Thalmann Buy $55
Feb-23-17Initiated Stifel Buy $38
Jan-25-17Initiated Robert W. Baird Outperform $43
Jun-20-16Initiated Piper Jaffray Overweight $33
Jun-20-16Initiated Citigroup Buy
May-23-19 01:47AM  Edited Transcript of RETA earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents -5.30%
May-22-19 12:46PM  Reata's drug, Bardoxolone, shows promising results for chronic kidney disease Yahoo Finance Video
May-09-19 08:23PM  Reata Pharmaceuticals, Inc. (RETA) Q1 2019 Earnings Call Transcript Motley Fool
07:55AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:45AM  Reata Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results and an Update on Development Programs GlobeNewswire
May-06-19 03:26PM  Biotech developing kidney disease treatment jumps after hedge fund recommendation at conference CNBC +5.77%
May-02-19 04:15PM  Reata Announces Presentation at the Annual CKD3 Chronic Kidney Disease Drug Development Summit GlobeNewswire
06:45AM  Reata Pharmaceuticals, Inc. to Report First Quarter 2019 Financials and to Provide an Update on Development Programs on May 9, 2019 GlobeNewswire
May-01-19 12:45PM  Did Hedge Funds Drop The Ball On Reata Pharmaceuticals, Inc. (RETA) ? Insider Monkey
Apr-30-19 07:52AM  Reata Pharmaceuticals, Inc. (NASDAQ:RETA): When Will It Breakeven? Simply Wall St.
Apr-02-19 03:20PM  Reata CEO on drug that shows signs of reversing kidney damage CNBC Videos +7.29%
Mar-15-19 11:43AM  Edited Transcript of RETA earnings conference call or presentation 28-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Feb-28-19 11:56AM  Reata Pharmaceuticals, Inc. (RETA) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:45AM  Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2018 Financials and Operating Results GlobeNewswire
Feb-25-19 12:59PM  Who Has Been Buying Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shares? Simply Wall St.
Feb-22-19 10:30AM  Analysts Estimate Reata Pharmaceuticals, Inc. (RETA) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-21-19 06:45AM  Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2018 Financials and to Provide an Update on Development Programs GlobeNewswire
Feb-20-19 06:45AM  Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in Patients with Focal Segmental Glomerulosclerosis and in Patients From All Four Cohorts of PHOENIX GlobeNewswire
Feb-05-19 07:45AM  Analysis: Positioning to Benefit within LPL Financial, The Andersons, Del Frisco's Restaurant Group, United Fire Group, Reata Pharmaceuticals, and Federal Agricultural Mortgage Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-07-19 07:15AM  Reata Pharmaceuticals, Inc. Appoints Geoffrey A. Block, M.D. as Vice President, Nephrology GlobeNewswire +23.24%
Jan-04-19 09:02AM  2 Promising Biotech Stocks That Insiders Are Snapping Up TheStreet.com +13.74%
Jan-03-19 04:01PM  Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease GlobeNewswire -6.87%
Dec-19-18 01:17AM  Reata Pharmaceuticals, Inc. (RETA): Hedge Funds Are Snapping Up Insider Monkey
Nov-26-18 08:55AM  Report: Exploring Fundamental Drivers Behind Reata Pharmaceuticals, Calyxt, SIFCO Industries, EchoStar, Tel-Instrument Electronics, and United States Antimony New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +6.68%
Nov-19-18 05:53PM  Edited Transcript of RETA earnings conference call or presentation 7-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-18 11:20AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Lags Revenue Estimates Zacks +13.41%
07:00AM  Reata Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results and an Update on Development Programs GlobeNewswire
Oct-31-18 04:35PM  Reata Pharmaceuticals, Inc. to Report Third Quarter 2018 Financial Results and Provide an Update on Development Programs on Wednesday, November 7, 2018 GlobeNewswire
Oct-16-18 07:05AM  Reata Announces Presentation of Four Clinical Abstracts at the American Society of Nephrology Kidney Week 2018 GlobeNewswire
Oct-09-18 07:40AM  Research Report Identifies Cerner, Reata Pharmaceuticals, Lennar, Acacia Communications, GoPro, and ProAssurance with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-25-18 07:00AM  Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in IgA Nephropathy and Type 1 Diabetic Chronic Kidney Disease GlobeNewswire
Sep-21-18 08:58AM  Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock? Zacks
Sep-18-18 08:24AM  Who Just Ramped Up Their Shares In Reata Pharmaceuticals Inc (NASDAQ:RETA)? Simply Wall St.
Aug-30-18 06:40PM  Reata Announces Receipt of $30 Million Milestone Payment From Kyowa Hakko Kirin GlobeNewswire
Aug-22-18 11:41AM  Edited Transcript of RETA earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 08:05PM  Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM  Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs GlobeNewswire
Aug-06-18 05:35PM  Reata Pharmaceuticals, Inc. to Report Second Quarter 2018 Financial Results and an Update on Development Programs on Wednesday, August 8, 2018 GlobeNewswire
Jul-28-18 08:38AM  3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys? Motley Fool
Jul-27-18 11:05AM  Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-25-18 08:30AM  Investor Expectations to Drive Momentum within Reata Pharmaceuticals, Shoe Carnival, United Fire Group, Approach Resources, Saul Centers, and Tennant Discovering Underlying Factors of Influence GlobeNewswire
Jul-24-18 08:52PM  Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Public Offering GlobeNewswire
12:40PM  These Biotech Stocks Should Be On Your Watch-List ACCESSWIRE
08:00AM  Todays Research Reports on Stocks to Watch: Reata Pharmaceuticals and LifePoint Health ACCESSWIRE
Jul-23-18 04:57PM  Here's Why Reata Pharmaceuticals Skyrocketed 65% Today Motley Fool +64.98%
04:39PM  Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock GlobeNewswire
06:45AM  Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in CKD Caused by Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease GlobeNewswire
Jul-17-18 09:38AM  Can The Uptrend Continue for Reata Pharmaceuticals (RETA)? Zacks
Jul-10-18 04:18PM  Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of Friedreichs Ataxia GlobeNewswire
Jun-20-18 04:18PM  Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of RORt GlobeNewswire
Jun-14-18 04:15PM  Reata Pharmaceuticals, Inc. Secures $125 Million Term Loan Facility GlobeNewswire
Jun-04-18 07:30AM  Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease GlobeNewswire
Jun-01-18 04:15PM  Reata Selected to Present Early-Stage Programs at the BIO International Convention GlobeNewswire
08:16AM  Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO Benzinga
May-31-18 04:15PM  Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome GlobeNewswire
May-30-18 07:00AM  Wired News - Reata Pharma Presented Encouraging Interim Data from PHOENIX Trial Assessing Bardoxolone Methyl in Patients with ADPKD and IgA Nephropathy ACCESSWIRE
May-25-18 03:30AM  Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study GlobeNewswire
May-18-18 08:30AM  Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathan's Famous, United Fire Group, and Intercept Pharmaceuticals Future Expectations, Projections Moving into 2018 GlobeNewswire
May-15-18 01:51PM  Edited Transcript of RETA earnings conference call or presentation 9-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-08-18 05:00PM  Reata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results and an Update on Development Programs GlobeNewswire
Apr-24-18 04:15PM  Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreichs Ataxia and Other Severe Neurological Diseases GlobeNewswire
Apr-11-18 04:15PM  Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome GlobeNewswire
Apr-03-18 07:30AM  Reata to Present Preclinical Data on RTA 1701, a Novel RORt Inverse Agonist, at Upcoming Immunology Conference GlobeNewswire +6.56%
Mar-29-18 04:15PM  Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan GlobeNewswire
Mar-26-18 07:10AM  Wired News Reata Pharma Reports Positive Top-line Data from its Phase-2 LARIAT Trial ACCESSWIRE
Mar-22-18 07:30AM  Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial GlobeNewswire
Mar-20-18 08:20AM  Report: Developing Opportunities within Super Micro Computer, Post, Reata Pharmaceuticals, Landstar System, Central Garden & Pet, and Albany International Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-16-18 04:15PM  Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference GlobeNewswire
Mar-02-18 07:30AM  Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2017 Financial and Operating Results GlobeNewswire -7.04%
Mar-01-18 05:14PM  Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies GlobeNewswire
Feb-27-18 04:15PM  Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials GlobeNewswire
Feb-12-18 04:15PM  Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial GlobeNewswire
Jan-18-18 04:15PM  Reata Announces the Publication of Efficacy Data From the Beacon Study of Bardoxolone in Diabetic CKD in the American Journal of Nephrology GlobeNewswire
Jan-17-18 07:50AM  Report: Developing Opportunities within Repligen, Avid Technology, Reata Pharmaceuticals, Stellus Capital Investment, American Financial Group, and Actuant Future Expectations, Projections Moving into 2018 GlobeNewswire
Dec-14-17 06:45PM  Who Owns Most Of Reata Pharmaceuticals Inc (NASDAQ:RETA)? Simply Wall St.
Dec-11-17 07:30AM  Reata Pharmaceuticals, Inc. Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma GlobeNewswire -8.31%
Nov-30-17 02:19PM  ETFs with exposure to Reata Pharmaceuticals, Inc. : November 30, 2017 Capital Cube
Nov-29-17 07:24AM  Reata Pharmaceuticals, Inc. :RETA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-13-17 07:30AM  Reata Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial and Operating Results GlobeNewswire -8.60%
Nov-09-17 08:33AM  Is a Surprise Coming for Reata Pharmaceuticals (RETA) This Earnings Season? Zacks
Nov-06-17 07:30AM  Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting GlobeNewswire
Nov-03-17 11:00AM  Reata Announces Primary Results from the Phase 2 CARDINAL Study of Bardoxolone in Alport Syndrome at the American Society of Nephrology Kidney Week 2017 Annual Meeting GlobeNewswire
Oct-30-17 12:47PM  Reata Pharmaceuticals, Inc. Value Analysis (NASDAQ:RETA) : October 30, 2017 Capital Cube
Oct-27-17 08:29AM  Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RETA-US : October 27, 2017 Capital Cube
Oct-26-17 10:45AM  ETFs with exposure to Reata Pharmaceuticals, Inc. : October 26, 2017 Capital Cube
Oct-23-17 07:30AM  Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreichs Ataxia GlobeNewswire
Oct-20-17 11:03AM  Reata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual Meeting GlobeNewswire
Sep-13-17 05:26PM  Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma GlobeNewswire
Sep-01-17 09:54AM  Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RETA-US : September 1, 2017 Capital Cube
Aug-31-17 08:31PM  ETFs with exposure to Reata Pharmaceuticals, Inc. : September 1, 2017 Capital Cube
07:10AM  Featured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in Europe ACCESSWIRE
Aug-25-17 10:56AM  Reata Pharmaceuticals, Inc. :RETA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-15-17 06:42PM  Reata Pharmaceuticals, Inc. Value Analysis (NASDAQ:RETA) : August 15, 2017 Capital Cube
Aug-14-17 04:01PM  Reata Pharmaceuticals, Inc. Announces Second Quarter 2017 Financial and Operating Results GlobeNewswire
07:00AM  FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreichs Ataxia GlobeNewswire
Aug-07-17 05:15PM  Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome GlobeNewswire
Aug-01-17 10:28AM  Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
09:17AM  Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RETA-US : August 1, 2017 Capital Cube
Jul-26-17 07:18PM  Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Public Offering GlobeNewswire
Jul-25-17 04:05PM  Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock GlobeNewswire -8.32%
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wilson Jason DouglasChief Financial OfficerMay 15Sale89.914,000359,6310May 17 11:47 AM
Wilson Jason DouglasChief Financial OfficerApr 15Sale83.824,000335,2620Apr 16 02:21 PM
Castellanos ElainePrincipal Accounting OfficerApr 08Sale90.172,000180,3402,138Apr 09 05:24 PM
Wilson Jason DouglasChief Financial OfficerMar 19Sale93.5128,3962,655,2090Mar 21 03:23 PM
Wilson Jason DouglasChief Financial OfficerMar 18Sale95.111,604152,5560Mar 19 05:32 PM
Wilson Jason DouglasChief Financial OfficerMar 15Sale93.624,000374,4700Mar 19 05:32 PM
WORTLEY MICHAEL DChief Legal OfficerMar 05Sale100.1626,9402,698,4410Mar 07 05:22 PM
Castellanos ElainePrincipal Accounting OfficerMar 05Sale102.003,588365,9762,138Mar 07 05:12 PM
Bass James EdwardDirectorMar 05Sale100.295,852586,92011,703Mar 07 05:05 PM
Ward Keith WayneChief Development OfficerFeb 26Sale91.2125,1842,296,9328,620Feb 27 04:22 PM
Ward Keith WayneChief Development OfficerFeb 25Sale91.0015,1831,381,6538,620Feb 27 04:22 PM
Wilson Jason DouglasChief Financial OfficerFeb 15Sale85.444,000341,7600Feb 19 01:50 PM
Wilson Jason DouglasChief Financial OfficerFeb 05Sale80.003,000240,0000Feb 06 01:01 PM
Ward Keith WayneChief Development OfficerJan 31Sale76.704,150318,3028,620Feb 01 11:50 AM
Wilson Jason DouglasChief Financial OfficerJan 15Sale71.154,000284,5890Jan 16 04:26 PM
Wilson Jason DouglasChief Financial OfficerJan 07Sale72.0420,0001,440,8200Jan 09 04:43 PM
Ward Keith WayneChief Development OfficerJan 02Sale53.994,150224,0450Jan 03 02:45 PM
Bass James EdwardDirectorDec 20Buy52.1288846,28754,110Dec 21 09:45 AM
CPMG IncDirectorDec 12Buy59.901,41884,931281,918Dec 12 05:57 PM
Traweek James W JR10% OwnerDec 12Buy59.901,41884,9313,023,349Dec 12 05:59 PM
McGaughy R Kent JrDirectorDec 12Buy59.901,41884,9313,023,349Dec 12 05:58 PM
McGaughy R Kent JrDirectorDec 11Buy60.0752,8093,172,3373,021,931Dec 12 05:58 PM
Traweek James W JR10% OwnerDec 11Buy60.0752,8093,172,3373,021,931Dec 12 05:59 PM
CPMG IncDirectorDec 11Buy60.0752,8093,172,337109,408Dec 12 05:57 PM
CPMG IncDirectorDec 10Buy58.7756,5993,326,56656,599Dec 12 05:57 PM
Traweek James W JR10% OwnerDec 10Buy58.7756,5993,326,5662,969,122Dec 12 05:59 PM
McGaughy R Kent JrDirectorDec 10Buy58.7756,5993,326,5662,969,122Dec 12 05:58 PM
Bass James EdwardDirectorNov 16Buy59.331,67999,61553,222Nov 19 11:57 AM
Ward Keith WayneChief Development OfficerNov 07Sale66.974,750318,1090Nov 08 11:16 AM
Ward Keith WayneChief Development OfficerNov 01Sale59.484,750282,5300Nov 01 05:18 PM
Ward Keith WayneChief Development OfficerOct 23Sale57.0814,250813,3900Oct 24 11:01 AM
Bass James EdwardDirectorJul 25Buy78.3488869,56651,543Jul 26 01:22 PM
Castellanos ElainePrincipal Accounting OfficerJul 23Sale50.817,336372,7640Jul 25 04:06 PM
Ward Keith WayneChief Development OfficerJul 05Sale36.624,750173,9450Jul 09 11:16 AM
Ward Keith WayneChief Development OfficerJun 05Sale36.6228,5001,043,6700Jun 07 11:37 AM